[go: up one dir, main page]

FI101194B1 - Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmistamiseksi - Google Patents

Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmistamiseksi

Info

Publication number
FI101194B1
FI101194B1 FI911309A FI911309A FI101194B1 FI 101194 B1 FI101194 B1 FI 101194B1 FI 911309 A FI911309 A FI 911309A FI 911309 A FI911309 A FI 911309A FI 101194 B1 FI101194 B1 FI 101194B1
Authority
FI
Finland
Prior art keywords
preparations
lyophilized
dicarboxylic acid
disclosed
lyophilate
Prior art date
Application number
FI911309A
Other languages
English (en)
Swedish (sv)
Other versions
FI911309A (fi
FI911309A0 (fi
FI101194B (fi
Inventor
Andreas Leo Johannes De Meere
Marinus Arie De Ruiter
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI911309A0 publication Critical patent/FI911309A0/fi
Publication of FI911309A publication Critical patent/FI911309A/fi
Application granted granted Critical
Publication of FI101194B1 publication Critical patent/FI101194B1/fi
Publication of FI101194B publication Critical patent/FI101194B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
FI911309A 1990-03-20 1991-03-18 Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmis tamiseksi FI101194B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90200665 1990-03-20
EP90200665 1990-03-20

Publications (4)

Publication Number Publication Date
FI911309A0 FI911309A0 (fi) 1991-03-18
FI911309A FI911309A (fi) 1991-09-21
FI101194B1 true FI101194B1 (fi) 1998-05-15
FI101194B FI101194B (fi) 1998-05-15

Family

ID=8204967

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911309A FI101194B (fi) 1990-03-20 1991-03-18 Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmis tamiseksi

Country Status (16)

Country Link
EP (1) EP0448146B1 (fi)
JP (1) JP3031570B2 (fi)
KR (1) KR100221123B1 (fi)
AT (1) ATE107172T1 (fi)
AU (1) AU631730B2 (fi)
CA (1) CA2037884C (fi)
DE (1) DE69102465T2 (fi)
DK (1) DK0448146T3 (fi)
ES (1) ES2057731T3 (fi)
FI (1) FI101194B (fi)
HK (1) HK1002494A1 (fi)
ID (1) ID905B (fi)
IE (1) IE64738B1 (fi)
NZ (1) NZ237458A (fi)
PT (1) PT97074B (fi)
ZA (1) ZA911659B (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
AU679986B2 (en) * 1993-04-28 1997-07-17 N.V. Organon Lyospheres comprising gonadotropin
JP4165878B2 (ja) * 1993-06-03 2008-10-15 株式会社林原生物化学研究所 トレハロース遊離酵素とその製造方法並びに用途
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
DK0814841T3 (da) * 1995-03-21 2002-03-04 Applied Research Systems Flydende hCG-formuleringer
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
NZ508874A (en) * 1998-07-23 2004-03-26 Lilly Co Eli FSH and FSH variant formulations, products and methods of treating infertility.
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
TWI277425B (en) 1999-04-13 2007-04-01 Lilly Co Eli Pulmonary administration of dry powder formulations for treating infertility
AU2002210749B2 (en) * 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical Sustained release preparations
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
KR101105486B1 (ko) * 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1638595B1 (en) 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
SG151298A1 (en) 2004-04-08 2009-04-30 Biomatrica Inc Integration of sample storage and sample management for life science
WO2007095337A2 (en) * 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
NZ583991A (en) 2007-11-01 2012-02-24 Merck Serono Sa Luteinizing hormone liquid formulations
CN101269215B (zh) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 一种糖蛋白激素组合物
CA2761675A1 (en) 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
MY171140A (en) 2012-01-27 2019-09-27 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ,インク. 周囲温度における血小板の安定化
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
IT1057895B (it) * 1975-02-17 1982-03-30 Serono Lab Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration

Also Published As

Publication number Publication date
FI911309A (fi) 1991-09-21
PT97074B (pt) 1998-10-30
ES2057731T3 (es) 1994-10-16
JPH04217630A (ja) 1992-08-07
DE69102465T2 (de) 1995-03-02
KR100221123B1 (ko) 1999-09-15
ATE107172T1 (de) 1994-07-15
CA2037884C (en) 2003-10-21
ID905B (id) 1996-09-10
ZA911659B (en) 1991-12-24
FI911309A0 (fi) 1991-03-18
IE910732A1 (en) 1991-09-25
EP0448146B1 (en) 1994-06-15
JP3031570B2 (ja) 2000-04-10
AU7362391A (en) 1991-09-26
EP0448146A1 (en) 1991-09-25
CA2037884A1 (en) 1991-09-21
FI101194B (fi) 1998-05-15
HK1002494A1 (en) 1998-08-28
DE69102465D1 (de) 1994-07-21
AU631730B2 (en) 1992-12-03
DK0448146T3 (da) 1994-10-24
KR910016340A (ko) 1991-11-05
NZ237458A (en) 1992-02-25
IE64738B1 (en) 1995-09-06
PT97074A (pt) 1991-10-31

Similar Documents

Publication Publication Date Title
FI101194B1 (fi) Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmistamiseksi
DE69232847T2 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
TR199800062A2 (xx) S�v� gonadotropin ihtiva eden form�lasyonlar.
US6117984A (en) Growth hormone crystals and a process for production of these GH-crystals
RU98100930A (ru) Жидкие композиции, содержащие гонадотропин
EP0355460A3 (en) Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
DE3881281T2 (de) Stabilisierter attenuierter lebender impfstoff und seine herstellung.
JP3702313B2 (ja) ゴナドトロピン含有薬剤組成物
KR970706841A (ko) 성장호르몬 및 루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and leucine)
IL86638A0 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives,their preparation and their use as pesticides
DE59008754D1 (de) Verfahren zur Herstellung von granuliertem Natriumacetat-Trihydrat.
KR950704494A (ko) 수두-대상포진 바이러스(vzv)에 대한 백신(vaccines against varicellazoster virus(vzv))
TH23071B (th) สูตรผสมของเหลวที่มีโกนาโดโทรพิน
JPS643160A (en) (2-cyano-2-oxyiminoacetyl)-amino acid derivative

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: N.V. ORGANON

Free format text: N.V. ORGANON